+

NO20001240L - Kay-A immune system protein - Google Patents

Kay-A immune system protein

Info

Publication number
NO20001240L
NO20001240L NO20001240A NO20001240A NO20001240L NO 20001240 L NO20001240 L NO 20001240L NO 20001240 A NO20001240 A NO 20001240A NO 20001240 A NO20001240 A NO 20001240A NO 20001240 L NO20001240 L NO 20001240L
Authority
NO
Norway
Prior art keywords
kay
immune system
system protein
tnf
ligands
Prior art date
Application number
NO20001240A
Other languages
Norwegian (no)
Other versions
NO20001240D0 (en
Inventor
Jurg Tschopp
Original Assignee
Apotech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotech Sa filed Critical Apotech Sa
Publication of NO20001240D0 publication Critical patent/NO20001240D0/en
Publication of NO20001240L publication Critical patent/NO20001240L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Kay-ligand, et nytt medlem av tumornekrosefaktorfamilien (TNF), modifiserte Kay-ligander og farmasøytiske sammen- setninger omfattende disse.Kay ligand, a new member of the tumor necrosis factor family (TNF), modified Kay ligands and pharmaceutical compositions comprising these.

NO20001240A 1997-09-12 2000-03-09 Kay-A immune system protein NO20001240L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
PCT/US1998/019037 WO1999012964A2 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein

Publications (2)

Publication Number Publication Date
NO20001240D0 NO20001240D0 (en) 2000-03-09
NO20001240L true NO20001240L (en) 2000-05-10

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001240A NO20001240L (en) 1997-09-12 2000-03-09 Kay-A immune system protein

Country Status (17)

Country Link
EP (1) EP1012270A2 (en)
JP (1) JP2001515711A (en)
KR (1) KR20010023892A (en)
CN (1) CN1269832A (en)
AU (1) AU9315298A (en)
BR (1) BR9812433A (en)
CA (1) CA2303424A1 (en)
EA (1) EA200000311A1 (en)
EE (1) EE200000148A (en)
HU (1) HUP0004034A3 (en)
IL (1) IL134480A0 (en)
IS (1) IS5375A (en)
NO (1) NO20001240L (en)
PL (1) PL339740A1 (en)
SK (1) SK3532000A3 (en)
TR (1) TR200000654T2 (en)
WO (1) WO1999012964A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
CA2310987A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
WO2000043032A2 (en) * 1999-01-25 2000-07-27 Biogen, Inc. Baff, inhibitors thereof and their use in the modulation of b-cell response
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
EP1860190A3 (en) * 1999-02-23 2008-03-12 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variants
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
US6475987B1 (en) 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
BR0013391A (en) * 1999-08-17 2002-07-09 Biogen Inc Use of the baff receptor (bcma) as an immunoregulatory agent
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
CA2399387C (en) 2000-02-11 2015-11-03 Biogen, Inc. Heterologous polypeptide of the tnf family
IL150755A0 (en) 2000-02-16 2003-02-12 Genentech Inc Uses of agonists and antagonists to modulate activity of tnf-related molecules
CA2408617A1 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
MXPA02012434A (en) 2000-06-16 2004-09-06 Cambridge Antibody Tech Antibodies that immunospecifically bind to blys.
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
WO2002018620A2 (en) * 2000-08-15 2002-03-07 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
PL393317A1 (en) 2001-05-11 2011-05-23 Amgen Inc. Peptides and related binding molecules TALL-1
AR035119A1 (en) 2001-08-16 2004-04-14 Lilly Co Eli ANTI-HTNFSF13B HUMAN ANTI-BODIES
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
CA2526402A1 (en) 2003-06-05 2005-01-20 Genentech, Inc. Blys antagonists and uses thereof
KR20070001880A (en) 2003-10-20 2007-01-04 바이오겐 아이덱 엠에이 인코포레이티드 Therapeutic regimens for ＢΑFF antagonists
JP2008505607A (en) * 2004-01-29 2008-02-28 ジェネンテック・インコーポレーテッド BCMA extracellular domain variants and methods of use thereof
KR20070100228A (en) 2004-10-05 2007-10-10 제넨테크, 인크. How to treat vasculitis
CA2583900A1 (en) 2004-10-13 2006-04-27 The Washington University Use of baff to treat sepsis
JP2008525002A (en) 2004-12-23 2008-07-17 ラボラトワール セローノ ソシエテ アノニム BCMA polypeptides and uses thereof
CN101262876A (en) 2005-08-09 2008-09-10 酶遗传学股份有限公司 Method of treating B cell malignancies with TACI-IG fusion molecules
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
KR20090016707A (en) 2006-05-15 2009-02-17 아레스 트레이딩 에스.에이. How to treat autoimmune diseases using TACIBIV fusion molecules
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
JP6271254B2 (en) 2011-02-28 2018-01-31 ジェネンテック， インコーポレイテッド Methods for predicting biological markers and responses to B cell antagonists
ES2829499T3 (en) 2013-02-05 2021-06-01 Engmab Sarl Method for the selection of antibodies against BCMA
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
WO2015155332A1 (en) 2014-04-11 2015-10-15 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018325A1 (en) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
AU6166396A (en) * 1995-06-07 1996-12-30 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical prepara tions
DE69635088T3 (en) * 1996-10-25 2012-01-26 Human Genome Sciences, Inc. NEUTROKIN alpha
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5

Also Published As

Publication number Publication date
HUP0004034A2 (en) 2001-03-28
PL339740A1 (en) 2001-01-02
EP1012270A2 (en) 2000-06-28
SK3532000A3 (en) 2001-12-03
JP2001515711A (en) 2001-09-25
TR200000654T2 (en) 2000-07-21
HUP0004034A3 (en) 2002-08-28
IL134480A0 (en) 2001-04-30
EA200000311A1 (en) 2000-10-30
WO1999012964A3 (en) 1999-05-27
CN1269832A (en) 2000-10-11
KR20010023892A (en) 2001-03-26
AU9315298A (en) 1999-03-29
NO20001240D0 (en) 2000-03-09
IS5375A (en) 2000-02-11
CA2303424A1 (en) 1999-03-18
EE200000148A (en) 2001-02-15
BR9812433A (en) 2000-09-26
WO1999012964A2 (en) 1999-03-18

Similar Documents

Publication Publication Date Title
NO20001240L (en) Kay-A immune system protein
NO20084906L (en) DNA sequence encoding tumor necrosis factor-related ligand (TRELL), host organism transformed with such DNA as well as TRELL, preparation and use thereof in the preparation of drugs and antibodies
WO1999012965A3 (en) April- a novel protein with growth effects
EP0724456A4 (en) ANTIBODIES DIRECTED AGAINST CD40
TR199500854A2 (en) Proteins from the liver of mammals and their use in oncology.
HUP0100452A2 (en) Levosimendan preparations that can be administered through the mucous membrane
NO892589L (en) DELAYED CROSS BINDING SYSTEM FOR FRACTURING FLUIDS.
NO903650D0 (en) BLUE ACTIVATOR IN THE FORM OF GRANULATED PARTICLES.
DE69726602D1 (en) Hepatitis b inhibitoren
NO970895D0 (en) Phenyl peptides, process for their preparation, and pharmaceutical preparations containing these peptides
IT8919481A0 (en) ARTICULATING SYSTEM FOR FURNITURE AND ITS ASSEMBLY PROCEDURE.
ZA903843B (en) Tumor necrosis factor binding protein ii,its purification and antibodies thereto
DK1019500T3 (en) IFN receptor 1 binding proteins, DNA encoding them, and methods for modulating cellular response to interferons
ITTO960379A0 (en) PHARMACEUTICAL COMPOSITION FOR CARDIOVASCULAR AND KIDNEY DISEASES.
FR2747681B1 (en) ADENOVIRAL DODECAEDRIC PROTEIN COMPLEX, COMPOSITION CONTAINING THE SAME AND ITS APPLICATIONS
EP0596725A3 (en) Drug resistance-conferring protein, antibodies reactive therewith and utilities thereof.
NO893397L (en) PROCEDURE FOR CLEANING AN AIR FLOW FOR HIGHLY DISPERSED SOLID PARTICLES.
NO905200D0 (en) PREPARATIONS CONTAINING MAGNETIC PARTICLES.
BR7302483U (en) Dual flow radial turbocharger
KR970053646U (en) A pump that forcibly crushes particles such as pigments, drugs, and foods and forcibly transports them
NO913819L (en) LINING ROOMS AND PROCEDURE FOR ASSEMBLY OF THE SAME.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载